Kazuya Sakai1, Hideo Yagi1, Masaki Hayakawa1, Kaori Harada2, Tatsuhiko Someya2, Yoshihiro Fujimura3, Masanori Matsumoto1 (1.Department of Blood Transfusion Medicine, Nara Medical University, Nara, Japan, 2.TAGCyx Biotechnologies Inc, Tokyo, Japan, 3.Japanese Red Cross Kinki Brock Blood Center, Osaka, Japan)
Session information
Oral Session
Oral Session 2-13A Platelet
Sat. Oct 13, 2018 9:00 AM - 10:00 AM No.13 (Osaka International Convention Center, 11F 1101-2)
Chair: Hirokazu Kashiwagi (Osaka University Graduate School of Medicine, Department of Hematology and Oncology, Japan)
Akihiro Otsu1, Shugo Kowata1, Ryo Togawa1, Tadashi Shimoyama1, Maki Nishiya1, Norifumi Sugawara1, Ryousei Sasaki1, Wataru Izumita1, Satsuki Kamihara1, Yasuhiko Tsukushi1, Tatsuo Oyake1, Kazunori Murai2, Yoji Ishida1, Takashi Ishida1 (1.Hematol., Iwate Med Univ., Iwate, Japan, 2.Hematol., Iwate Prefectural Central Hospital, Iwate, Japan)
Yukako Ono-Uruga1, Masaki Yazawa2, Keiichi Tozawa3, Taisuke Mori4, Yasuo Ikeda5, Yumiko Matsubara1,6 (1.Clinical and Translational Research Center, Keio University, Tokyo, Japan., 2.Department of Plastic and Reconstructive Surgery, Keio University, Tokyo, Japan., 3.Division of Hematology, Keio University, Tokyo, Japan., 4.Department of Pathology, National Cancer Center Hospital, Tokyo, Japan., 5.Life Science and Medical Bioscience, Waseda University, Tokyo, Japan., 6.Department of Laboratory Medicine, Keio University, Tokyo, Japan)
Yumi Ogura1, Makiko Mori2, Katsuyoshi Koh2, Hiroshi Yoshino3, Noritaka Niyazawa3, Masatoshi Tokita3, Chihaya Imai4, Yohichiro Hirata5, Ryo Inuduka5, Shinji Kunishima6, Shigeaki Nonoyama1, Hiroyuki Kawaguchi1 (1.Pediatr., National Defense Medical College, Saitama, Japan, 2.Department of Hematology-Oncology, Saitama Children's Medical Center, Saitama, 3.Department of Pediatrics, Kyorin University, Tokyo, 4.Department of Homeostatic Regulation and Development, Niigata University, Niigata, 5.Department of Pediatrics, University of Tokyo, Japan, 6.Clinical Research Center, Nagoya Medical Center, Nagoya)
Keigo Akuta1, Kazunobu Kiyomizu1, Hirokazu Kashiwagi1, Shinji Kunishima2, Fumiaki Banno3, Koichi Kokame3, Nobuko Nishiura1, Yoichiro Morikawa1, Hisashi Kato1, Shigenori Honda3, Yuzuru Kanakura1, Toshiyuki Miyata4, Yoshiaki Tomiyama5 (1.Department of Hematology and Oncology, Osaka University, Suita, Japan, 2.Clinical Research Center, Nagoya Medical Center, Nagoya, Japan, 3.Department of Molecular Pathogenesis, National Cerebral Cardiovascular Center, Suita, Japan, 4.Department of Cerebrovascular Medicine, National Cerebral Cardiovascular Center, Suita, Japan, 5.Department of Blood Transfusion, Osaka University Hospital, Suita, Japan)
Sou Nakamura1, Yukitaka Ito1,2, Naoshi Sugimoto1,3, Yoshikazu Kato4, Shinya Sakuma5, Keitaro Ito5, Hiroki Kumon5, Mikiko Ohno6, Eiichiro Nishi6, Fumihito Arai5, Satoshi Nishimura7, Koji Eto1,8 (1.Center for iPS Cell Research and Application, Kyoto University, Kyoto., 2.Kyoto Development Center, Megakaryon Corporation, Kyoto., 3.Department of Hematology, Kagawa University Hospital, Kagawa., 4.Mixing Technology Laboratory, SATAKE Chemical Equipment MFG. LTD., 5.Department of Micro-Nano Systems Engineering, Nagoya University, Nagoya., 6.Department of Pharmacology, Shiga University of Medical Science, Otsu., 7.Center for Molecular Medicine, Jichi Medical University, Tochigi., 8.Department of Regenerative Medicine, Chiba University, Chiba.)